Alan Oglesby

2.9k total citations · 1 hit paper
55 papers, 2.2k citations indexed

About

Alan Oglesby is a scholar working on Infectious Diseases, Endocrinology, Diabetes and Metabolism and Virology. According to data from OpenAlex, Alan Oglesby has authored 55 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 13 papers in Endocrinology, Diabetes and Metabolism and 12 papers in Virology. Recurrent topics in Alan Oglesby's work include HIV/AIDS drug development and treatment (19 papers), HIV/AIDS Research and Interventions (19 papers) and HIV Research and Treatment (12 papers). Alan Oglesby is often cited by papers focused on HIV/AIDS drug development and treatment (19 papers), HIV/AIDS Research and Interventions (19 papers) and HIV Research and Treatment (12 papers). Alan Oglesby collaborates with scholars based in United States, United Kingdom and Canada. Alan Oglesby's co-authors include Adam Gordois, Paul Scuffham, Arran Shearer, Janet Tobian, Kristina Secnik, Risa P. Hayes, Andrew Palmer, William J. Valentine, Aaron I. Vinik and Etta J. Vinik and has published in prestigious journals such as Diabetes Care, Journal of Bone and Mineral Research and Bone.

In The Last Decade

Alan Oglesby

53 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Health Care Costs of Diabetic Peripheral Neuropathy in the U.S.

2003 572 citations Adam Gordois, Paul Scuffham et al. profile →

Peers

Countries citing papers authored by Alan Oglesby

Since Specialization

Citations

This map shows the geographic impact of Alan Oglesby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Oglesby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Oglesby more than expected).

Fields of papers citing papers by Alan Oglesby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Oglesby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Oglesby. The network helps show where Alan Oglesby may publish in the future.

Co-authorship network of co-authors of Alan Oglesby

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Oglesby. A scholar is included among the top collaborators of Alan Oglesby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Oglesby. Alan Oglesby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States 2024 ·PharmacoEconomics ·Anita J. Brogan, (unknown), (unknown), Jeremy Fraysse, (unknown), Alan Oglesby	1
2	Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study 2024 ·AIDS and Behavior ·Princy Kumar, Amanda Clarke, (unknown), Miguel García Deltoro, Simona Di Giambenedetto, Carlos Brites, Laurent Hocqueloux, Po‐Liang Lu, J Oyee, Alan Oglesby, Brian Wynne, (unknown), (unknown), (unknown), (unknown), Julie Priest	0
3	Pre-Exposure Prophylaxis for the Prevention of HIV-1: An Assessment of Oral Pre-Exposure Prophylaxis Usage Patterns, First Evidence of HIV-1, and HIV-1 Risk Factors in the United States 2024 ·AIDS Patient Care and STDs ·Alan Oglesby, Guillaume Germain, (unknown), François Laliberté, (unknown), (unknown), Heidi Swygard, Mei Sheng Duh	1
4	Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup Analyses 2024 ·Infectious Diseases and Therapy ·Paul Benson, (unknown), Cynthia Donovan, (unknown), (unknown), (unknown), (unknown), Hannah Wallis, Andrew P. Brogan, (unknown), Alan Oglesby	1
5	Virologic Outcomes Among People Living With Human Immunodeficiency Virus With High Pretherapy Viral Load Burden Initiating on Common Core Agents 2021 ·Open Forum Infectious Diseases ·Anthony Mills, Kathy L. Schulman, Jennifer S Fusco, Michael Wohlfeiler, Julie Priest, Alan Oglesby, Laurence Brunet, Philip Lackey, Gregory Fusco	3
6	Retrospective analysis of adherence to HIV treatment and healthcare utilization in a commercially insured population 2021 ·Journal of Medical Economics ·Julie Priest, Rachel H. Bhak, Maral DerSarkissian, Alan Oglesby, (unknown), (unknown), (unknown), Mei Sheng Duh, Cindy Garris	6
7	853. Real-World Persistency of Patients Receiving Tenofovir-Based Pre-Exposure Prophylaxis for the Prevention of HIV Infection in the US 2021 ·Open Forum Infectious Diseases ·Alan Oglesby, Guillaume Germain, François Laliberté, (unknown), Heidi Swygard, (unknown), (unknown), Mei Sheng Duh	1
8	Clinical characteristics and treatment patterns among US patients with HIV. 2019 ·PubMed ·Julie Priest, Tanya Burton, Cori Blauer‐Peterson, (unknown), Alan Oglesby	4
9	Benchmarking HIV Quality Measures Across US Payer Types 2019 ·Population Health Management ·Julie Priest, Debra E. Irwin, Kristin Evans, Alan Oglesby, (unknown)	5
10	PIN29 ESTIMATION OF THE CLINICAL OUTCOMES AND COST-EFFECTIVENESS OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A TEST AND TREAT (T&T) ANTIRETROVIRAL (ARV) REGIMEN FOR TREATMENT-NAIVE PATIENTS WITH HIV-1 INFECTION IN THE UNITED STATES 2019 ·Value in Health ·Alan Oglesby, Christopher Nguyen, (unknown), Sarah‐Jane Anderson, P McEwan, (unknown), Tom Ward	1
11	2485. Real-world Experience with Dolutegravir Plus Rilpivirine Two-Drug Regimen 2019 ·Open Forum Infectious Diseases ·Douglas Ward, (unknown), Moti Ramgopal, David J. Riedel, Cindy Garris, Alan Oglesby, John Waller, Jenna Roberts, (unknown), (unknown), (unknown), (unknown), Joseph Mrus, James Pike	1
12	A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings 2015 ·Clinical Therapeutics ·Xuehua Ke, (unknown), Alan Oglesby, Jeetvan Patel, Hong Kan, Robert Boggs	12
13	The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain 2009 ·European Journal of Cancer Care ·Rhys Pockett, Daniel Castellano, Phil McEwan, Alan Oglesby, BL Barber, Karen Chung	97
14	The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy 2008 ·Health and Quality of Life Outcomes ·Louis S. Matza, Matthew D. Rousculp, Karen G. Malley, Kristina S. Boye, Alan Oglesby	45
15	Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes 2006 ·Health and Quality of Life Outcomes ·Kristina S. Boye, Louis S. Matza, Alan Oglesby, Karen G. Malley, Sunny Kim, Risa P. Hayes, Robert G. Brodows	63
16	The association between diabetes related medical costs and glycemic control: A retrospective analysis 2006 ·Cost Effectiveness and Resource Allocation ·Alan Oglesby, Kristina Secnik, John Barron, Ibrahim Al‐Zakwani, Maureen J. Lage	110
17	The health care costs of diabetic nephropathy in the United States and the United Kingdom 2004 ·Journal of Diabetes and its Complications ·Adam Gordois, Paul Scuffham, Arran Shearer, Alan Oglesby	81
18	What Impact Would Pancreatic Beta-cell Preservation Have on Life Expectancy, Quality-adjusted Life Expectancy and Costs of Complications in Patients with Type 2 Diabetes? A Projection Using the CORE Diabetes Model 2004 ·Current Medical Research and Opinion ·Andrew Palmer, Stéphane Roze, William J. Valentine, Michael E. Minshall, Morten Lammert, Alan Oglesby, (unknown), Giatgen A. Spinas	13
19	The healthcare costs of diabetic peripheral neuropathy in the UK. (Cost-of-illness study) 2003 ·RADIOISOTOPES ·Adam Gordois, Paul Scuffham, Arran Shearer, Alan Oglesby	16
20	Intervention thresholds for osteoporosis 2002 ·Bone ·J. A. Kanis, Olof Johnell, Anders Odén, Chris De Laet, Alan Oglesby, B Jönsson	64

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact